title: From the laboratory to the clinic: How translational studies in animals have lead to clinical advances in boron neutron capture therapy.
abstract: In this report five examples have been selected to illustrate how studies in experimental animals have lead directly to clinical implementation. These include (1) the use of BSH as a boron delivery agent for BNCT of patients with brain tumors, and more specifically gliomas; (2) the use of BPA as a delivery agent for BNCT for patients with melanomas and (3) its subsequent use for BNCT of patients with gliomas; (4) optimization of the delivery of BPA in patients with gliomas; and finally (5) the combination of BSH and BPA with BNCT alone or together with X-irradiation to treat patients with gliomas.
authors.affiliation: The Ohio State University, Department of Pathology, 4132 Graves Hall, 333W. 10th Avenue, Columbus, OH 43210, USA. Electronic address: rolf.barth@osumc.edu.
authors.forename: Rolf F
authors.initials: RF
authors.lastname: Barth
mesh_terms: D000818:Animals; D001896:Boron Compounds / Q000008:administration & dosage; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000532:radiotherapy; D008545:Melanoma / Q000532:radiotherapy; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D057170:Translational Research, Biomedical
chemical_list: D001896:Boron Compounds; D010649:Phenylalanine; C033685:4-boronophenylalanine
keywords: Boronophenylalanine (BPA); Melanomas and brain tumors; Optimization of delivery of BSH and BPA; Sodium borocaptate (BSH)